Journal
LUNG CANCER
Volume 89, Issue 2, Pages 218-221Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2015.05.009
Keywords
Lung cancer; Intensive care; Targeted therapy; ALK gene rearrangement; Ceritinib; Clinical trials
Categories
Ask authors/readers for more resources
Lung cancer is the most common solid tumor that requires admission to an intensive care unit (ICU). The overall perception about the value of ICU admission for lung cancer patients remains negative, given the poor overall prognosis of patients with advanced lung cancer. Recently developed highly effective targeted therapies for lung cancers with an oncogene driver have an expected rapid onset of action and a decreased risk of toxicity. Therefore, ICU care for lung cancer patients has to be reconsidered. We present an illustrative case of a young woman with stage IV ALK-translocated pulmonary adenocarcinoma. Her disease dramatically worsened while waiting for central confirmation of the ALK-translocation to start treatment in a clinical trial with ceritinib, a 2nd generation ALK tyrosine kinase inhibitor. She needed mechanical ventilation and veno-venous extracorporal membranous oxygenation, to have sufficient time to recover from overwhelming bilateral lung adenocarcinoma, while on treatment. She is now doing fine 1 year later. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available